JP2008518943A - Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン - Google Patents

Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン Download PDF

Info

Publication number
JP2008518943A
JP2008518943A JP2007539241A JP2007539241A JP2008518943A JP 2008518943 A JP2008518943 A JP 2008518943A JP 2007539241 A JP2007539241 A JP 2007539241A JP 2007539241 A JP2007539241 A JP 2007539241A JP 2008518943 A JP2008518943 A JP 2008518943A
Authority
JP
Japan
Prior art keywords
patient
hours
hcv
administering
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007539241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518943A5 (enExample
Inventor
チュ・フイ−メイ
エネ・エッテ
リンジー・マクネア
ジョン・アラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2008518943A publication Critical patent/JP2008518943A/ja
Publication of JP2008518943A5 publication Critical patent/JP2008518943A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007539241A 2004-10-29 2005-10-31 Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン Pending JP2008518943A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62354204P 2004-10-29 2004-10-29
US67940205P 2005-05-09 2005-05-09
US68209105P 2005-05-17 2005-05-17
US72274605P 2005-09-30 2005-09-30
PCT/US2005/039240 WO2006050250A2 (en) 2004-10-29 2005-10-31 Dose forms comprising vx-950 and their dosage regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013001638A Division JP2013060474A (ja) 2004-10-29 2013-01-09 Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン

Publications (2)

Publication Number Publication Date
JP2008518943A true JP2008518943A (ja) 2008-06-05
JP2008518943A5 JP2008518943A5 (enExample) 2008-12-18

Family

ID=36120273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007539241A Pending JP2008518943A (ja) 2004-10-29 2005-10-31 Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン
JP2013001638A Pending JP2013060474A (ja) 2004-10-29 2013-01-09 Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013001638A Pending JP2013060474A (ja) 2004-10-29 2013-01-09 Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン

Country Status (14)

Country Link
US (1) US8431615B2 (enExample)
EP (2) EP2500021A1 (enExample)
JP (2) JP2008518943A (enExample)
KR (2) KR20130063022A (enExample)
CN (1) CN102988365A (enExample)
AU (1) AU2005302361B2 (enExample)
CA (1) CA2585647A1 (enExample)
IL (1) IL182847A0 (enExample)
MX (1) MX2007005179A (enExample)
MY (1) MY141025A (enExample)
NO (1) NO20072733L (enExample)
RU (1) RU2393863C2 (enExample)
TW (2) TWI437990B (enExample)
WO (1) WO2006050250A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503669A (ja) * 2008-09-24 2012-02-09 バーテックス ファーマシューティカルズ インコーポレイテッド 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ
JP2012517478A (ja) * 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) * 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
AR049297A1 (es) * 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
JP5160415B2 (ja) * 2005-06-02 2013-03-13 メルク・シャープ・アンド・ドーム・コーポレーション 医薬処方物およびそれを用いる治療方法
WO2006130688A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Compounds for inhibiting cathepsin activity
EP1891089B1 (en) * 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
RU2441020C2 (ru) * 2005-08-02 2012-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серинпротеазы
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
CA2666814A1 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
BRPI0807907A2 (pt) * 2007-02-27 2017-05-16 Vertex Pharma co-cristais e composições farmacêuticas compreendendo os mesmos.
CN101903392A (zh) * 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
JP2010528013A (ja) * 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン
TW200922933A (en) * 2007-08-30 2009-06-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
AU2008309589B2 (en) 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
EP2214682A2 (en) * 2007-11-05 2010-08-11 Vertex Pharmaceuticals Incorporated Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
EP2444070A1 (en) * 2008-02-28 2012-04-25 Abbott Laboratories Tablets
BRPI0911673A2 (pt) * 2008-04-23 2017-12-05 Vertex Pharma tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068278A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Ex vivo modifiable medicament release-associations
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
EP2358439A1 (en) * 2008-11-05 2011-08-24 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
DE102008064038A1 (de) * 2008-12-22 2010-07-01 Ksb Aktiengesellschaft Vorrichtung und Verfahren zur Detektion von Belägen
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP2528605A1 (en) * 2010-01-29 2012-12-05 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
CA2815416A1 (en) 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042570A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
WO2005123076A2 (en) * 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090914B1 (en) 1992-12-29 2003-01-02 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO1997040028A1 (en) 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
CA2282398A1 (en) 1997-03-14 1998-09-17 Steven M. Ronkin Inhibitors of impdh enzyme
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
CN1230198C (zh) * 1998-05-15 2005-12-07 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
WO2000056331A1 (en) 1999-03-19 2000-09-28 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AP2001002290A0 (en) 1999-04-07 2001-12-31 Pfizer Prod Inc Use of CYP2D6 inhibitors in combination therapies.
CN1387606A (zh) * 1999-09-06 2002-12-25 创新内燃机技术股份有限公司 车用燃烧发动机和运行一种车用燃烧发动机的方法
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
RU2192881C1 (ru) * 2001-03-01 2002-11-20 Сибирский государственный медицинский университет Способ лечения хронических вирусных гепатитов
JP5024497B2 (ja) * 2001-03-27 2012-09-12 キユーピー株式会社 経口用肌改善剤、肌改善方法及び肌改善用食品組成物
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
RU2207869C1 (ru) * 2002-04-04 2003-07-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Фармацевтическая твердая композиция на основе эналаприла малеата и способ ее получения
AU2003269890A1 (en) * 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
MXPA05001298A (es) 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2006517960A (ja) 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
WO2004101602A2 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
CA2538843A1 (en) 2003-09-12 2005-03-24 Vertex Pharmaceuticals Incorporated Animal model for protease activity and liver damage
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
KR20120091276A (ko) 2004-02-20 2012-08-17 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042570A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
WO2005123076A2 (en) * 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5007019017; 'ＶＥＲＴＥＸ　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬＳ　ＰＲＥＳＳ　ＲＥＬＥＡＳＥ' ［ＯＮＬＩＮＥ］ , 20040907 *
JPN5007019018; ＴＡＮ　Ｓ-Ｌ: ＣＵＲＲＥＮＴ　ＯＰＩＮＩＯＮ　ＩＮ　ＰＨＡＲＭＡＣＯＬＯＧＹ Ｖ４　Ｎ５, 200410, Ｐ４６５-４７０, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ　ＰＵＢＬＩＳＨＥＲＳ *
JPN5007019019; 'ＰＲＥＣＬＩＮＩＣＡＬ　ＤＡＴＡ　ＳＵＧＧＥＳＴ　ＰＯＴＥＮＴＩＡＬ　ＦＯＲ　ＯＲＡＬ　ＣＯＭＢＩＮＡＴＩＯＮ　ＡＰＰＲＯＡＣＨＥＳ　ＦＯＲ　ＨＣＶ' ［ＯＮＬＩＮＥ］ , 20040531 *
JPN6011040838; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ．，　２７９［１７］　（２００４　Ａｐｒ）　ｐ．１７５０８-１４．　Ｅｐｕｂ　２００４　Ｆｅｂ　６． *
JPN6011040839; Ｎａｔｕｒｅ，　４２６　（２００３）　ｐ．１８６-１８９ *
JPN6011040842; 内科，　９３［３］　（２００４．０３．０１）　ｐ．４８２-４８６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503669A (ja) * 2008-09-24 2012-02-09 バーテックス ファーマシューティカルズ インコーポレイテッド 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ
JP2012517478A (ja) * 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤

Also Published As

Publication number Publication date
MY141025A (en) 2010-02-25
US8431615B2 (en) 2013-04-30
AU2005302361A1 (en) 2006-05-11
WO2006050250A2 (en) 2006-05-11
EP1819336A2 (en) 2007-08-22
MX2007005179A (es) 2008-03-06
KR20130063022A (ko) 2013-06-13
US20060105978A1 (en) 2006-05-18
EP2500021A1 (en) 2012-09-19
TW200630093A (en) 2006-09-01
TW201424733A (zh) 2014-07-01
RU2007119725A (ru) 2008-12-20
JP2013060474A (ja) 2013-04-04
RU2393863C2 (ru) 2010-07-10
KR20070085547A (ko) 2007-08-27
WO2006050250A3 (en) 2006-07-27
CA2585647A1 (en) 2006-05-11
AU2005302361B2 (en) 2011-11-17
CN102988365A (zh) 2013-03-27
TWI437990B (zh) 2014-05-21
NO20072733L (no) 2007-05-29
IL182847A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
AU2005302361B2 (en) Dose forms comprising VX-950 and their dosage regimen
EP1677827B1 (en) Combinations for hcv treatment
US20100189688A1 (en) Dose forms comprising VX-950 and their dosage regimen
US8664273B2 (en) Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
JP2012503669A (ja) 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ
JP2010526143A (ja) Ｈｃｖ感染の処置のための併用療法
AU2012200942A1 (en) Dose forms comprising VX-950 and their dosage regimen
HK1178451A (en) Dose forms comprising vx-950 and their dosage regimen
HK1148962A (en) Dose forms comprising vx-950 and their dosage regimen
HK1158507A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha-2a/2b and ribavirin
EP1944042A1 (en) Combinations for HCV treatment
HK1109064A (en) Dose forms comprising vx-950 and their dosage regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140418

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140625